AVBP ArriVent BioPharma, Inc.

8-K Current Report

Filed: March 17, 2026

Health Care

Pharmaceutical Preparations

ArriVent BioPharma, Inc. (AVBP) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• Firmonertinib (EGFR inhibitor) and ARR-002 (MUC16/NaPi2b tetravalent ADC) preclinical data to be presented at 2026 AACR Annual Meeting
• ARR-002 is a novel dual-target ADC — early pipeline asset; AACR presentation marks first public preclinical data disclosure

+1 more insights

Item 8.01 · Other Events

• ArriVent BioPharma (AVBP) issued a press release containing material information disclosed under Item 8.01
• Full details available in the referenced exhibit — filing text itself contains no disclosed figures or event specifics

Other ArriVent BioPharma, Inc. 8-K Filings

8-K Mar 5, 2026

Get deeper insights on ArriVent BioPharma, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.